Inherited Retinal Dystrophy Primarily Involving Sensory Retina Clinical Trial
Official title:
A Cross-over Randomized Control Trial to Evaluate the Retinaldehyde Dehydrogenase Inhibitor, Disulfiram, in Improving Retinal Sensitivity in Eyes Affected by Inherited Retinal Degeneration
Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03561922 -
Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS
|
N/A | |
| Recruiting |
NCT04131400 -
Establishment of the National Registry for Inherited Retinal Dystrophy in Iran
|
||
| Completed |
NCT03613948 -
Study on the Effects of Mutations Under Inherited Retinal Disease in Korean
|